4/17
02:33 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $12.00. They now have a "neutral" rating on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $12.00. They now have a "neutral" rating on the stock.
3/26
02:01 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was given a new $24.00 price target on by analysts at Leerink Partners.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was given a new $24.00 price target on by analysts at Leerink Partners.
3/20
08:05 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
3/19
09:15 am
rgnx
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
Medium
Report
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
3/17
08:27 am
rgnx
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner [Yahoo! Finance]
Low
Report
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner [Yahoo! Finance]
3/17
08:06 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $36.00 to $34.00. They now have a "buy" rating on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $36.00 to $34.00. They now have a "buy" rating on the stock.
3/14
08:36 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at Morgan Stanley from $22.00 to $24.00. They now have an "overweight" rating on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at Morgan Stanley from $22.00 to $24.00. They now have an "overweight" rating on the stock.
3/14
08:36 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
3/13
06:46 pm
rgnx
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript [Seeking Alpha]
3/13
04:18 pm
rgnx
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates [Yahoo! Finance]
Low
Report
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates [Yahoo! Finance]
3/13
04:05 pm
rgnx
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Low
Report
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
3/12
05:39 pm
rgnx
REGENXBIO Inc. (RGNX) Stock [Seeking Alpha]
Medium
Report
REGENXBIO Inc. (RGNX) Stock [Seeking Alpha]
3/10
07:05 am
rgnx
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Low
Report
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
3/7
02:00 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/4
07:56 am
rgnx
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases [Yahoo! Finance]
Low
Report
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases [Yahoo! Finance]
3/4
07:31 am
rgnx
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
Neutral
Report
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
2/26
04:40 pm
rgnx
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
Low
Report
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
2/26
04:05 pm
rgnx
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Low
Report
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
2/25
11:05 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/25
04:19 pm
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
04:05 pm
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences
Low
Report
REGENXBIO to Participate in Upcoming Investor Conferences
2/21
02:30 pm
rgnx
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
Low
Report
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
2/15
01:05 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/11
07:17 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $14.00 price target on the stock, down previously from $38.00.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $14.00 price target on the stock, down previously from $38.00.
2/8
06:51 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at Raymond James to a "moderate buy" rating.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at Raymond James to a "moderate buy" rating.